



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In Re Application of:

Jenny Louie-Helm et al.

Examiner: Blessing M. Fubara

Serial No.: 10/773,986

Group Art Unit: 1618

Filing Date: February 5, 2004

Confirmation No: 7141

Title: FORMULATION OF AN ERODIBLE, GASTRIC RETENTIVE ORAL DOSAGE
FORM USING IN VITRO DISINTEGRATION TEST DATA

AMENDMENT UNDER 37 CFR 1.111 PURSUANT TO 37 CFR 1.114

Mail Stop RCE

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Sir:

Responsive to the final Office Action mailed from the PTO on August 30, 2005, please reconsider the application in view of this response. As this response is timely filed within the 3-month shortened statutory period for reply, no extension fee accompanies this filing.

Accompanying this filing is a Request for Continued Examination (RCE). As the finality of the office action will be withdrawn upon entry of the RCE, this response is filed pursuant to 37 CFR §1.111.

Listing of the Claims: The Listing of the Claims is set forth on pages 2 to 5 of this document.

Remarks: Applicants' Remarks in support of this application are set forth on pages 6 to 10 of this document.

Attachments: Attached to the end of this document is a copy of USP 24-NF 19 § 701.